RAMP 202: A phase 2 study of avutometinib (VS-6766) ± defactinib, in patients with advanced KRAS G12V mutant non–small cell lung cancer (NSCLC).
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Joshua E. Reuss, Sunil G. Gandhi, David R. Spigel, Pasi A. Janne, Luis G. Paz-Ares, Shirish M. Gadgeel, Jyoti D. Patel, Francesco Passiglia, Alexander I. Spira, Martin Joseph Edelman, George R. Blumenschein, Ardaman Shergill, Timothy F. Burns, Vijeta Bhambhani, Gloria Patrick, Jonathan A. Pachter, Louis J. Denis, D. Ross Camidge
Institutions: Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Florida Cancer Specialists & Research Institute, Tennessee Oncology, Dana-Farber Cancer Institute, Universidad Complutense de Madrid, Hospital Universitario 12 De Octubre, Henry Ford Health, Northwestern University, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, University of Turin, Fox Chase Cancer Center, The University of Texas MD Anderson Cancer Center, University of Chicago, University of Chicago Medical Center, University of Pittsburgh, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Verastem (United States), University of Colorado Anschutz
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Verastem Oncology
OpenAlex ID: W4379340596